01411
). Low-dose lenalidomide was started on day +24 at a dose of 10 mg per day and 8 days later at day +32, the ALC rose further to 8366 cells/µl while the serum free kappa light chain level decreased to 9500 mg/L, the 24 hour urinary Bence Jones protein decreased to 1.3 g/24 hours and the calcium level became normal at 9.1 mg/dl. By day +38, a marrow examination showed a dramatic increase in the marrow-infiltrating CD8+ T-cells to 70% while the marrow plasmacytosis was decreased to ~ 15% with extensive CD138+ myeloma cell necrosis (see Fig 3c) . Over the next month, the patient experienced a return to a good quality of life and the 24 hour urinary excretion of Bence Jones protein decreased to as low 280 mg/24 hours.
While immunoassays showed early detection of the gene-marked cells (see Figure 2) , during the period of major clinical response, the CD8+ T-cell compartment was comprised of 2 dominant the study had measurable baseline levels of paraprotein. Of these 11, paraprotein levels decreased to undetectable levels by the initial tumor assessment at 6 weeks post-transplant in six patients (not shown). Of these six, patients 259 and 204 showed improvement in disease response as measured by immunofixation between the first and second tumor assessment period (Supplementary Table 1) . 5 patients experienced a gradual decrease in paraprotein levels over time, as shown in this Figure. Note that lenalidomide maintenance was not started until day 100 post-transplant, and therefore improvements between day 42 and 100 are independent of this immune modulator. Patients 260 and 252 experienced declines after day 100 but did not receive lenalidomide maintenance (Supplementary Table 1 ). Notably patients 207 and 211 who had light chain only tumor, also experienced a gradual improvement of their disease between the first and second tumor assessment period (reference Supplementary Table 1 
